Charles River Laboratories International, Inc. Aktie News

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, today announced a gene therapy contract development and manufacturing organization (CDMO) collaboration, providing plasmid DNA for AAV production and in vitro efficacy studies. “We are excited to build a strong collaboration with Gazi University,...

NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.

Charles River Laboratories International, Inc. (CRL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Charles River Laboratories said on Monday it would buy one of its major suppliers of non-human primates for about $510 million as the contract research firm seeks greater control over procurement of the animals used in drug safety testing.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Provides Business Updates.

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CDMO--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the second cohort of its Cell & Gene Therapy Incubator Program (CIP). Launched in December 2024, with the inaugural cohort announced in April 2025, the program provides early-stage biotechnology pioneers with access to extensive scientific and commercial expertise, as we...